NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-21-266 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the creation and utilization of Patient Safety Learning Laboratories (PSLL). These learning laboratories are places and networks where transdisciplinary teams identify closely related threats to diagnostic or treatment efforts associated with a high burden of harm and cost. Following a systems engineering methodology, the learning laboratories stretch professional boundaries, envision innovative designs, and take advantage of brainstorming and rapid prototyping techniques that other leading industries employ. Promising prototypes undergo further develop-test-revise iterations, and subsequent integration as a working system. After further improvements are made to the integrated working system, its efficacy is evaluated in a realistic simulated or clinical setting.
Notice NOT-CA-21-090 from the NIH Guide for Grants and Contracts
Notice NOT-HG-21-032 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-040 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.
Notice NOT-MH-21-270 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-005 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-066 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-22-003 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse [NIDA] seeks research proposals to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to an abused drug (including opioids, cocaine and stimulants, cannabinoids, and nicotine). The overall goal is to determine the contributions of antiretroviral [ARV] treatment regimens that are used to suppress viral load in the neurological and neurocognitive deficits that are associated with HIV-Associated Neurocognitive Disorders [HAND].
Funding Opportunity RFA-AG-22-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose to add enhanced measures of educational experiences, cognitive function, or both to existing studies and/or to conduct analyses that incorporate these measures to clarify the relationship between education, cognition, and risk of Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD), including the role of education in social disparities in AD/ADRD outcomes.
Notice NOT-CA-21-083 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-250 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.
Notice NOT-HD-21-027 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-135 from the NIH Guide for Grants and Contracts
Notice NOT-NR-21-005 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-034 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-006 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-050 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-089 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-085 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-054 from the NIH Guide for Grants and Contracts